Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome†1.Collaborative Group of the Société de Néphrologie: A. Meyrier, Coordinator (Bobigny); J. Pollini (Avignon); E. Mac Namara (Béthune); B. Bourbigot, J. Cledes, R. Tanneau (Brest); J.P. Ryckelynck (Caen); P. Freida, J. Potier (Cherbourg); M. Tolani (Compiègne); O. Kourilsky (Evry); J.J. Haultier Freyming-Merlebach); M. Leski (Genève); J. Maurizi, P. Zaoui (Grenoble); F. Babinet, P. Lebon (Le Mans); B. François, R. Cahen (Lyon); P. Duhoux (Luxembourg); M. Olmer (Marseille); D. Kleinknecht (Montreuil); J. Guenel (Nantes); E. Cassuto-Viguier (Nice); J.C. Gardin, M. Paillard, J.L. Tual, P. Lesavre (Paris); G. Touchard (Poitiers); J.P. Melin (Reims); B. Moulin, J.P. Fillastre (Rouen); P. Simon (St. Brieuc); F. Berthoux (St. Etienne); B. Birmelé, H. Nivet (Tours); R. Montagnac, F. Schillinger (Troyes); P. Coville (Vannes).Pathologists: L.H. Noël, Expert Pathologist (Paris); P. Callard, (Paris); A. Volant, J.P. Leroy (Brest); J.C. Mandard, B. Gallet (Caen); A. Dieny (Grenoble); B. Van Damme (Leuven); F. Dijoud, J. Gilly (Lyon); P. Casanova (Marseille); F. Buzelin, M.F. Le Bodic, Y. Lenne, F. Dubigeon (Nantes); E. Cassuto-Viguier (Nice); B. Mougenot, D. Nochy, H. Beaufils (Paris); G. Touchard (Poitiers); P. Birembaut (Reims); M.P. Ramée (Rennes); J. Metayer, J. Hemet (Rouen); J.C. Sabatier (St. Etienne); B. Laurent-Pilonchery (St. Priest en Jarez); A. Benatre (Tours).  by Meyrier, Alain et al.
Kidney International, Vol. 45 (1994), pp. 1446—1456
Long-term renal tolerance of cyclosporin A treatment in adult
idiopathic nephrotic syndrome
ALAIN MEYRIER, LAURE-HELENE NOEL, PASCAL AURICHE, PATRICE CALLARD, and the
COLLABORATIVE GROUP OF THE SOCIETE DE NEPHROLOGIE, with the technical assistance of
DOREEN BRONEER
Service de Néphrologie, Hôpital Avicenne, Bobigny; Laboratoire de Pathologie Rénale, INSERM U 90, Clinique Néphrologique, Hopital
Necker and Laboratoire d'Anatomie Pathologique, Hôpital Tenon, Paris, France
Long-term renal tolerance of cyclosporin A treatment in adult idio-
pathic nephrotic syndrome. Repeat renal biopsies and serial serum
creatinine measurements were done in 36 adults who were treated for
steroid-dependent or -resistant idiopathic nephrotic syndrome with 5.54
0.81 mg/kg/day of cyclosporin A (CsA). Pre-CsA renal biopsy (RB 1)
had been carried out 11.6 12.2 months prior to CsA treatment. It
showed minimal glomerular changes (MCD) in 22, and Ito 16 glomeruli
with lesions of focal segmental glomerulosclerosis (FSGS) per biopsy in
14. Pretreatment serum creatinine levels were (mol/liter) 97.6 39.4
and were higher in FSGS (117.1 48.3) than in MCD (85.2 26.9; P <
0.04). Repeat biopsy (RB2) was done after 19.6 15.2 months (6 to 78)
of CsA treatment. At this time, in 15 patients the minimal glomerular
lesions observed on RBI were unchanged, whereas in 7 patients lesions
of FSGS were now visible. In patients with FSGS on RB1 and RB2,
serum creatinine at the end of CsA treatment was 130.6 60.1
molIliter, significantly greater (P = 0.022) than the corresponding
levels in the subset with MCD (87.3 24.8). The contrast between the
remarkable stability of renal function in the patients with MCD and the
worsening of renal function in the subgroup with FSGS was explained
in the latter by an aggravation of renal histologic lesions, with a greater
number of glomeruli with FSGS, of obsolescent glomeruli, and of
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interstitial fibrosis/infiltrates. This aggravation of the primary renal
disease was observed in some cases where CsA had obtained partial or
even complete remission. Few of the tubular lesions and of vascular
changes were typical of CsA toxicity but rather suggested development
of the primary renal disease. In contrast, although some increase in the
degree of tubulointerstitial lesions was observed on RB2, the rating of
such lesions was much less severe in patients whose renal biopsy
showed persistently normal glomeruli after exposure to CsA. Overall,
the most severe interstitial/vascular lesions were observed in patients
treated with the highest CsA dosages, and the "cut-off" of dosage
safety appeared to be 5.5 mg/kg/day. Two patients died during the study
period. Long-term surveillance of the extant 34 patients showed that 8,
all of whom had FSGS, evolved to end-stage renal failure due to
progression of their primary renal disease after ending CsA treatment.
Four patients were failures of CsA and returned to conventional
therapy. CsA treatment was continued for 12 to 60 months in fourteen
patients who achieved remission. This treatment was progressively
tapered to a stop and they remained in remission without CsA (fol-
low-up 8 months to 6 years), indicating that in CsA responsive ne-
phrotic patients, mainly those with MCD, CsA dependency is far from
being the rule after a period of remission longer than one year.
Statistical analysis found three strong predictive factors of histological
CsA nephrotoxicity: a dosage greater than 5.5 mg/kg/day, presence of
renal insufficiency prior to treatment, and the percentage of glomeruli
with lesions of FSGS on initial renal biopsy. Conversely, in MCD with
normal renal function treated with less than 5.5 mg/kg/day, no correla-
tion was found between the development of tubulointerstitial/vascular
lesions and duration of CsA treatment. We conclude that: (I) treatment
of MCD with normal renal function, using a dosage of CsA up to 5.5.
mg/kg/day is safe and efficient; (2) conversely, FSGS with pre-existing
incipient renal insufficiency and tubulointerstitial lesions should be
considered as relatively hazardous; (3) repeat biopsy after a year of
treatment is necessary to determine whether treatment can be safely
continued or should be stopped; and (4) when prolonged remission has
been obtained with CsA treatment of more than a year, progressive
tapering of the drug to a stop is often followed by stable remission, a
finding which should lead to reconsidering the notion of "CsA depen-
dency" in CsA-responsive idiopathic nephrotic syndrome.
Idiopathic nephrotic syndrome ("lipoid nephrosis") com-
prises two histological subsets, minimal glomerular changes
(MCD) and focal segmental glomeruloscierosis (FSGS). Tran-
sition from the former to the latter is frequent in corticosteroid-
resistant forms [1]. Lipoid nephrosis, the most frequent cause
of nephrotic syndrome in childhood, represents more than 30%
of adult cases [2]. Its prognosis rests essentially on response to
therapy and glomerular histology [3]. Steroid-responsive MCD
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with infrequent relapses follow a favorable course. Steroid-
resistant FSGS has a 60% chance to evolve to chronic renal
failure [4—8}. Steroid-resistant or -dependent idiopathic ne-
phrotic syndrome may respond to alkylating agents, but the
response rate is low [91 and the margin between efficacy and
toxicity is narrow [10]. Steroid dependency with a high thresh-
old, or multiple relapses necessitating repeated courses of
glucocorticoids entail the multiple risks of steroid toxicity.
Reports on remission of nephrotic syndrome with cyclospo-
rin A (CsA) have appeared since 1985 [11, 12]. The acquired
experience [13] has determined that CsA exerts a suspensive,
not a curative effect on the nephrotic syndrome, which usually
relapses if treatment is stopped within the first year. This
indicates, at least during the first year of treatment, that steroid
dependency is traded off for CsA dependency. The nephrotoxic
potential of CsA has been amply documented [14—17]. Long-
term renal tolerance in a patient with nephrosis is therefore a
critical issue.
The experience concerning CsA efficacy in nephrotic syn-
drome is not matched by data on long-term tolerance. More
than 500 cases have been reported so far [11, 12, 18], but renal
tolerance was assessed over short periods of time and was
mainly based on follow-up of serum creatinine levels. Yet, data
originating from pediatric nephrologists have indicated that in
some instances chronic CsA toxicity was observed on repeat
biopsies in cases where stable serum creatinine levels were
falsely reassuring [19, 20]. Very few similar studies are avail-
able in the adult, that is, after the end of renal growth.
In 1985 studies were undertaken by the Sociëté de Néphrol-
ogie to assess the efficacy and the tolerance of CsA treatment in
adult idiopathic nephrotic syndrome [21]. Over five years, 112
patients were enrolled, of whom 106 were considered valid for
assessement of tolerance. In 36 of 106, tolerance was judged on
both renal function and repeat renal histology. Each was his
own control, as pretreatment biopsy had been carried out to
assess glomerular histology. The goal of this report is to analyze
the risk/benefit ratio of long-term CsA treatment in these 36
cases, to determine whether stable serum creatinine levels are
sufficient to pursue safely CsA treatment in an adult nephrotic
patient and to discuss the respective parts played by CsA and
by the natural course of the renal disease in the changes found
on repeat renal biopsies.
Brief interim reports on this study were presented in abstract
form at the 22nd Annual Meeting of the American Society of
Nephrology [22] and at the XIIth International Congress of
Nephrology [23].
Methods
Population studied
Complete details on inclusion/exclusion criteria, conduct of
the studies and clinical tolerance have been reported previously
[13, 21] and will only be summarized here. The 112 patients
were enrolled on the basis of: (i) resistance of nephrotic
syndrome to conventional treatment, including prednisone
and/or alkylating agents, or (ii) corticosteroid dependency with
unacceptable side effects, or (iii) in two cases a contraindication
to corticosteroids, leading to use CsA as first-line treatment.
Steroid resistance in this adult population was defined as
persistance of nephrotic syndrome after four months of pred-
nisone at a dosage of 1 mg/kg/day. This definition differs from
that accepted in pediatrics, where resistance is pronounced
after failure of four to six weeks of steroid treatment [3, 81. Such
extended time for determining steroid resistance in adult idio-
pathic nephrotic syndrome was confirmed in recent publica-
tions [24], although recently Ponticelli et al [18], in a random-
ized study concerning the efficacy of CsA treatment of
nephrotic syndrome, defined steroid resistance in adults as a
lack of response after a six week course of glucocorticoids.
The initial CsA dosage was S mg/kg/day, but investigators
were free to titrate dosage based on whole blood CsA assays,
clinical efficacy or both. Case by case analysis of patient
records showed that CsA dosage had been adjusted within a
range of 4 to 7.8 mg/kg/day.
Response was divided into complete remission (proteinuria
nil plus normal serum albumin levels), partial remission (24 hr
proteinuria comprised between 0.50 and 3 g and significant rise
in baseline serum albumin levels) and failure (24 hr proteinuria
>3 g and no change in serum albumin levels). In both studies,
after the end-point, investigators were free to resume or con-
tinue treatment. However, in these preliminary trials on the
adequacy and the safety of treating idiopathic nephrotic syn-
drome with a potentially nephrotoxic drug, the investigators
deemed that repeat renal biopsy was necessary in two circum-
stances. The first was partial remission, in a patient with clinical
improvement, reflected by control of edema and rising serum
albumin levels, in order to decide whether this symptomatic
improvement permitted continuing treatment without risk. The
second was to determine whether continuing treatment over the
following years was safe, irrespective of stability of renal
function.
All the data were entered into a computerized database in the
form of a Collaborative Registry. Information on each case was
obtained at regular intervals on patient follow-up forms. Data
were updated by telephone interviews when needed.
Criteria for patient selection
Among 106 patients with idiopathic nephrotic syndrome, 36
fulfilled the six following criteria and were selected for the
present study on that basis: (1) identification of the primary
renal disease (that is, MCD or FSGS) by renal biopsy carried
out before CsA treatment; (2) minimum duration of treatment of
six months; (3) full information as to dosages of CsA received
and regular follow-up of renal function; (4) repeat biopsy,
considered as the end-point of this study; (5) results of treat-
ment on nephrotic syndrome at end-point; and (6) information
concerning the subsequent evolution. No patient fulfilling these
criteria was omitted from the present study.
Conduct of the study
The experimental nature of CsA treatment of nephrosis and
the importance of a repeat renal biopsy was explained to all
patients, and informed consent was obtained in each case. Only
one repeat renal biopsy was complicated, in a patient who
willingly accepted to undergo a second repeat renal biopsy after
78 months of treatment with 6.9 mg/kg/day of CsA. Renal
biopsy was followed by symptomatic perirenal hematoma re-
quiring transfusion but with no further consequences. Overall,
the policy of repeat renal biopsy was not marred by an
unacceptable rate of iatrogenic complications, but in several
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Fig. 1. Arrowshows typical cyclosporin arteriolopathy (Patient 28). This arteriole is surrounded by severely damaged renal tissue with extensive
fibrosis and tubular damage. A glomerulus is visible, almost completely sclerosed by lesions of focal sclerosis (+).Thi biopsy was carried out in
a patient with steroid-resistant FSGS after 18 months of treatment with an average dosage of 7.8 mg/kg/day of CsA, at a time when serum creatinine
was 239 /Lmol/liter. The evolution was to end-stage renal failure and hemodialysis.
instances contributed to the decision to continue or stop treat-
ment, especially in cases with developing FSGS. Actually, the
decisions taken on the results of repeat renal biopsy were
revealed to be more ethical than blindly continuing CsA treat-
ment, relying only on monitoring of serum creatinine levels.
When the initial diagnosis was MCD and the last renal biopsy
dated from more than one year, renal histology was repeated
whenever possible shortly before enrollment in order to confirm
the adequacy of initial diagnosis and to exclude the possibility
of overlooked or newly appeared lesions of FSGS. Conversely,
when the histological diagnosis was FSGS, repeat renal sam-
pling was considered less necessary, at least for classification of
glomerular lesions. Patients were classified as MCD or FSGS,
and the presence of even one glomerulus with segmental lesions
on the biopsy sample was considered sufficient to exclude the
diagnosis of MCD.
Serum creatinine levels were measured weekly over three
weeks before inclusion to determine baseline renal function,
then weekly for the first month of treatment and monthly
thereafter.
Laboratory methods
Serum creatinine was measured by Technicon autoanalyzer.
Renal biopsies were done percutaneously and studied by light
microscopy after Masson's trichrome and silver staining, and
by immunofluorescence. Biopsies were forwarded by the pa-
thologists of the various referring centers to the coordinating
center. Each biopsy was coded and then interpreted by one of
us (L.H.N.), a member of a consensus group of renal patholo-
gists who had established a semi-quantitative rating applicable
to the renal lesions of CsA toxicity [17]. This pathologist was
unaware of whether the coded biopsy consisted of pre- or
post-CsA material, and of the clinical background of the corre-
sponding patient. The study of each biopsy included: total
number of glomeruli, number of obsolescent glomeruli, number
of glomeruli with lesions of FSGS, number of arterioles and
type of lesions thereof, finding of typical CsA arteriolopathy
consisting of necrosis of myocytes and protein deposition
within the vascular wall [25], an example of which is illustrated
in Figure 1, and presence and severity of arteriolar hyalinosis.
Minor vascular lesions with slight hyaline deposits which may
be observed in normal or elderly subjects were rated 1+. The
degree of tubulointerstitial damage was given special attention
and was rated from 0 to 4+, as: 0, no lesions; 1+, minor
changes; 2+, a few stripes of interstitial fibrosis with tubular
lesions and occasionally presence of obsolescent glomeruli
and/or vascular lesions within stripes; 3+, interstitial fibrosis!
infiltrates with tubular damage; and 4+, widespread renal tissue
damage. Representative examples of this classification are
shown in Figures 2, 3 and 4. At the cellular level, tubular lesions
considered typical of CsA toxicity [25] were isometric vacuol-
ization of epithelial cells and tubular cell calcification. The
practical goal of quantifying biopsies was twofold: first, to
determine the presence and severity of renal tissue lesions,
whether due to CsA nephrotoxicity or to the natural history of
the primary renal disease, in order to determine the safety of
continuing treatment; and second, to seek lesions considered
specific of CsA toxicity. Once the code was broken, the
biopsies were classified into pre- (RB1) and post-CsA (RB2).
The overall results are shown in Table 2. In this table, the RB 1
C .I
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Fig. 2. Example of renal biopsy rated 0. This repeat biopsy was carried out in Patient 4 after 12 months of treatment with CsA at an average
dosage of 5.5 mg/kg/day. The primary glomerulopathy was minimal change disease (silver staining, magnification: 100).
population can be broken down into two subgroups: patients 1
to 22 having no glomerular lesions and classified as MCD, and
patients 23 to 36 having at least one focal and segmental lesion,
classified as FSGS and who, in the process of quantifying the
lesions, were listed according to increasing number of affected
glomeruli (1 to 16). The adequacy of this initial, pre-CsA
classification was confirmed on RB2, as no patient identified as
FSGS on RB 1 had normal glomeruli on RB2.
Fig. 3. Example of renal biopsy rated +. Two stripes of sclerosis are visible, containing
tubulointerstitial space is fairly well preserved (silver staining, magnification: 100).
clusters of altered tubules. The rest of the
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Fig. 4. Example of renal biopsy rated + + +. Same patient as in Figure 1.
Statistical analysis
Statistical analysis was carried out with the GraphPAD InStat
computer program (GraphPAD, 1993, version 2.04) using Fish-
er's exact test for 2 by 2 tables for comparing qualitative
variables. Due to the non-Gaussian distribution of quantitative
data and the fact that groups had significantly different sDs,
unpaired nonparametric tests were used to assess significant
differences of means. Spearman nonparametric correlation tests
were used for assessing correlations among quantitative vari-
ables. A P value of <0.05 was considered significant.
Results
Evolution of renal function and nephrotic syndrome
a. All patients, N = 36. There were 26 males and 10 females,
aged 31 13 years (16 to 61), with no difference between
patients with MCD (32.6 12.8 years) and patients with FSGS
(28.4 13.3 years) (Table 1).
Duration of nephrotic syndrome before enrollment was 52.6
70.5 months (4 to 324). This duration had been shorter in the
14 patients with at least one glomerular lesion of FSGS (34.7
43.6 months) than in those with MCD (64.1 82.1 months).
This longer duration in MCD was explained by the greater
number of steroid-dependent, multirelapsing patients. The last
renal biopsy before commencing CsA treatment dated from 11.6
12.2 months (ito 59).
Serum creatinine at inclusion was 97.6 39.4 smo1/Iiter (49
to 210). Repeat renal biopsy was carried out after 19.6 15.2
months of CsA treatment (6 to 78). At that time, the average
dosage of CsA had been 5.54 0.81 mg/kg/day (4 to 7.8). Serum
creatinine level was 104.2 46.6 mol/liter (52 to 239). There
was no difference between the pre- and post-CsA serum creat-
mine levels (P = 0.65). The response of nephrotic syndrome to
CsA in the whole group was complete remission in 24 cases,
partial remission in six and failure in six.
b. Patients with an initial diagnosis of MCD, N = 22. The
time between last biopsy and enrollment was 11.4 13.7
months (ito 59). Three of four patients with an initial diagnosis
of MCD in whom RB 1 dated from more than 15 months (17 to
59) still had MCD on RB2, thus confirming the initial classifi-
cation. Pre-CsA serum creatinine level was 85.2 26.9 jxmoll
liter. Repeat biopsy was carried out after 21.6 17.1 months of
CsA treatment (6 to 78). Maximum dosage of CsA had been 5.26
0.59 mg/kg/day. At the time of repeat biopsy, serum creati-
nine level was 87.3 24.8 tmoU1iter (52 to 147). The response
of nephrotic syndrome to CsA in this subgroup was complete
remission in 19, partial remission in one, and failure in two.
c. Patients with an initial diagnosis of FSGS, N = 14. In 14
patients, initial renal biopsy showed one to 16 glomeruli with
lesions of FSGS. The average time between last biopsy and
enrollment was 11.9 9.9 months, and the longest interval was
36 months.
Pre-CsA serum creatinine was 117.1 48.3 j.mol/liter (60 to
210). This value was significantly greater than that of pre-CsA
serum creatinine in the MCD subgroup (P = 0.039). Repeat
renal biopsy was carried out after 16.4 11.6 months of CsA
treatment (7 to 78). The maximum dosage had been 5.96 0.94
mg/kg/day. At the time of repeat biopsy, serum creatinine level
was 130.6 60.1 smollliter (65 to 239). This value was
significantly greater than the corresponding serum creatinine at
the time of repeat biopsy in the subset with MCD (P = 0.02).
The pre- and post-C5A serum creatinine values in these patients
with FSGS were not significantly different (P = 0.39). The
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Table 1. Primary data concerning 36 patients with idiopathic nephrotic syndrome treated with CsA
All MCD P FSGS
Number of patients 36 22 14
M/F 26/10 14/8 NS 12/2
Age years 31.0 12.9
(16—fl)
32.6 12.8
(17—61)
NS 28.4 13.3
(16—61)
Duration of nephrotic syndrome 52.6 70.5 64.0 82.1 NS 34.7 43.6
before CsA Rx months (4—324) (4—324) (8—168)
Steroid status
Steroid-dependent 16 12 NS 4
Steroid-resistant
No steroid treatment
18
2
8 10
2 0
Interval between RB! and 11.6 12.2 11.4 13.7 NS 11.9 9.8
CsA Rx months (1—59) (1—59) (1—36)
Serum creatinine before 97.6 39.4 85.2 26.9 0.04 117.1 48.3
CsA Rx pnol/liter (49—210) (49—175) (60—210)
Maximum CsA dosage 5.54 0.81 5.26 0.59 0.07 5.96 0.94
mg/kg/day (4—7.8) (4-6.7) (4.8—7.8)
Exposure to CsA before 19.6 15.2 21.6 17.1 NS 16.4 11.6
RB2 months (6—78) (6—78) (7—53)
Serum creatinine at time of 104 46.6 87.3 24.8 0.02 130.6 60
RB2 (52—239) (52—147) (65—239)
Response to CsA
Complete remission
Partial remission
24
6
19
1
5
5(CR + PR) vs. F, NS
Failure 6 2 CR vs. (PR + F), P = 0.003 4
Abbreviations are: MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; CsA, cyclosporin A; Rx, treatment; RB!, last
renal biopsy before starting CsA treatment; RB2, repeat biopsy taken at end point of study.
response of nephrotic syndrome to CsA treatment in this
subgroup was complete remission in five, partial remission in
five, and failure in four.
Evolution of renal histology
a. Glomeruli. Three subgroups of patients can be distin-
guished on the basis of comparison of glomerular histology on
RB! and RB2.
Patients wit!: MCD on RBJ remaining MCD on RB2 (N =
15). In 15 patients RB2 showed normal glomeruli. The renal
tissue sample was small in two instances, where only three
glomeruli were obtained. In the 13 other patients the sample
was adequate, with an average of 16.8 6.4 glomeruli (10 to
34). Response to CsA in this subgroup of 15 was complete
remission in 13, partial remission in one and failure in one.
Exposure to the drug had been 20.8 13.2 months. Renal
function was remarkably stable, with pre-CsA serum creatinine
levels of 79.9 18.46 moU1iter and post-CsA serum creat-
mines of 80.4 16.18 pmo1Iliter.
Patients with FSGS on RBI and RB2 (N = 14). In 14 patients
the initial diagnosis of FSGS was confirmed on RB2. At this
time, five patients were in complete remission, five in partial
remission, and four were failures.
The number of glomeruli available on RB! and RB2 varied
somewhat for a given patient and among patients. Despite this
reservation, inherent in the renal biopsy technique, lesions of
FSGS were more severe and involved more glomeruli on RB2
than on RB 1, irrespective of response of nephrotic syndrome to
treatment. Overall, there were 60 of 314 (19.11%) glomeruli
with lesions of FSGS on RB! and 80 of 281 (28.47%; P =
0.0088) on RB2. There was a striking increase in the number of
obsolescent glomeruli, which rose from 9of314(2.87%) to 34 of
281 (12.1%; P < 0.0001). This aggravation of glomerular lesions
remained apparent when the counts were made excluding the
four patients with treatment failure. In the 10 patients with
partial or complete remission there were 53 of 249 (21.3%)
glomeruli with lesions of FSGS + obsolescent glomeruli on RB!
and 62 of 204 (30.4%) glomeruli with lesions of FSGS +
obsolescent glomeruli on RB2 (P = 0.03).
Even considering only the five patients with complete remis-
sion, there were 13 of 110 glomeruli with lesions of FSGS on
RB! (11.82%), compared to 21 of 97 on RB2 (21.65%). Despite
the small sample, this difference was significant (one-sided P
value of 0.0429).
Hence, whatever criterion is used concerning aggravation of
glomerular lesions (FSGS, obsolescent glomeruli, or both),
these lesions were more severe at the end of CsA treatment,
even in patients with partial or complete remission of protein-
uria.
Patients with MCD on RBJ and FSGS on RB2 (N = 7). In
seven patients MCD was diagnosed on RB! whereas lesions of
FSGS were found on RB2. A sampling error with overlooked
FSGS on RB! was considered unlikely in all, since the number
of glomeruli on RB! was equal to or greater than 10 (average
20.9 13.4, range 10 to 50). At the time of RB2, one patient was
a CsA treatment failure and six were in complete remission.
Exposure to CsA had been 23.29 24.75 months. Pre- and
post-CsA serum creatinine levels were unchanged (96.6 39.0
mollliter before CsA and 102.14 34.14 after CsA).
b. Vessels. Vascular lesions were present on RB! in 15
patients. They consisted in minor degrees of hyalinosis, rated
1+ in all. In patients with FSGS, these lesions accompanied
tubulointerstitial fibrosis and/or infiltrates and seemed to be
background noise, part of more generalized fibrotic phenomena
involving the other elements of the kidney. Vascular lesions
were not a prominent feature on RB2 in the patients with initial
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Table 2. Primary histological data concerning two subgroups within 36 patients treated with cyclosporin A for idiopathic nephrotic syndrome
MCD FSGS
RB! RB2RB! RB2
Glomeruli
Number (range) 20.7 14.8 (6—50) 16.8 9.3 (3—40) 22.4 12.5 (6—50) 20.1 12.! (4—50)
Obsolescent 0.73 1.42 (0—5) 1.1 1.6 (0—6) 0.64 1.34 (0—5) 2.43 3.16 (0—11)
FSGS 0 0 (0—0) 1.1 2.0 (0—6) 4.29 4.18 (1—16) 5.71 4.6 (1—16)
Vessels
# Arterioles 10.9 9.6 (0—33) 11.2 8.5 (1—30) 15.4 10.2 (0—29) 12.54 10.3 (0—30)
# With vacuoles 0.14 0.47 (0—2) 0.36 0.79 (0—3) 0.5 1(0—3) 0.64 1.01 (0—3)
# With CsA arteriolopathy 0 0 (0—0) 0.09 0.43 (0—2) 0.08 0.29 (0—1) 0.71 1.2 (0—3)
# With hyalinosis 0.73 1.24 (0—5) 1.14 1.73 (0—8) 1.58 1.88 (0—5) 1.43 1.65 (0—5)
Tubu!ointerstitial space
Tubular atrophy/dedifferation
0 14 5 5 1
+ 8 13 8 7
++ 0 4 1 3
+++ 0 0 0 2
++++ 0 0 0 1
Interstitial fibrosis
0 15 8 6 4
+ 0 9 8 4
++ 1 4 0 3
+++ 0 1 0 3
++++ 0 0 0 0
Interstitial infiltrates
0 20 15 10 5
+ 2 6 3 6
++ 0 1 1 2
+++ 0 0 0 1
÷+++ 0 0 0 0
Group 1 comprised 22 patients with an initial diagnosis of MCD, and Group 2, 14 patients with an initial diagnosis of FSGS. Abbreviations are
in Table!.
lesions of MCD. In only one case were they typical of vascular
CsA toxicity. In this patient exposure to CsA had been 78
months and the average CsA dosage had been 6.7 mg/kg/day. In
the subgroup with initial lesions of FSGS, four cases exhibited
vascular lesions with typical features of CsA toxicity. These
patients had been treated 53, 15, 18 and 26 months, with
dosages of respectively 6.6, 6.9, 7.8 and 7.3 mg/kg/day, that is,
well in excess of the average dosage used in the whole group.
c. Interstitium. Interstitial lesions were found on RB1 in 18
patients. They were rated 1 + in all but three cases. They were
mainly present in patients with an initial diagnosis of FSGS, and
mostly accompanied the glomerular and vascular lesions. Inter-
stitial lesions were distinctly more extensive on RB2 than on
RB 1. This was also true for patients with an initial diagnosis of
MCD which remained MCD on RB2, showing that even in this
subgroup with no glomerular lesions, CsA treatment induced
some degree of interstitial fibrosis and/or interstitial infiltrates
even though renal function remained unaltered. However, this
increase in interstitial fibrosis and/or interstitial infiltrates was
minor, with a majority of patients rated 0 on RB 1 who evolved
to 1+ on RB2. Only two of these patients had lesions rated 2+,
which were not considered sufficient to indicate that treatment
should be stopped. In contrast, the increase in interstitial
fibrosis showed a striking predominance in patients with FSGS.
In this subset, the development of interstitial fibrosis led to a
rating of 3 or 4+ in 6 of 14 cases. The overall rating, that is,
counting each + (plus) as one data point, yielded a total count
of 41 points on RB! (1.14 1.33 per patient) and 104 points on
RB2 (2.89 2.12 per patient; P < 0.0002). Again, the total
number of data points reflecting interstitial fibrosis on RB2 was
predominant in patients with FSGS (3.93 2.34 points per
patient) as opposed to MCD (2.23 1.72 points per patient; P
= 0.036).
Predictive factors of GsA histological toxicily
Statistical analysis was carried out in an endeavor to deter-
mine which elements were best predictive of development to
interstitial fibrosis, interstitial infiltrates and tubular atrophy
and/or dedifferentiation (Table 3). These three histological
criteria were pooled to represent overall insult to the tubuloin-
terstitium.
Age, gender and duration of nephrotic syndrome before CsA
bore no correlation with the risk of developing tubulointerstitial
lesions. In fact, patients with the longest duration of nephrotic
syndrome before CsA treatment was undertaken were mostly
those with steroid-dependent MCD, whose tolerance to CsA
regimen was the best. There was no correlation with the
duration of exposure to CsA before RB2 up to 78 months. There
was a strong correlation with initial serum creatinine value and
with the ratio of glomeruli with lesions of FSGS to total number
of glomeruli on pre-CsA biopsy. Regarding CsA dosage, 26
patients had received less than 5.6 mg/kg/day (4 to 5.5) and 10
patients had been treated with more than 5.6 mg/kg/day (5.7 to
7.8). The Mann-Whitney two-tailed test found a significant
difference in the degree of tubulointerstitial damage between
these two therapeutic modes (P = 0.017).
In summary, the three most important predictors of tubulo-
interstitial insult in the course of long-term CsA treatment of
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Table 3. Relationship between main variables and degree of tubulointerstitial lesions/fibrosis after treatment of adult idiopathic nephrotic
syndrome with CsA
Variables Test P r
Age Spearman nonparametric correlation 0.57 0.097
Gender Mann-Whitney 0.44
(M vs. F)
Duration of nephrotic syndrome Linear regression 0.43 —0.12
before CsA Rx Spearman nonparametric correlation 0.50
Duration of exposure to CsA Linear regression 0.99 0
before RB2 Spearman nonparametric correlation 0.99
CsA dosage Mann-Whitney 0.017
>5.5 vs. <5.6 mg/kg/day
Initial serum creatinine Linear regression 0.0031 0.39
at the time of RBI Spearman nonparametric correlation 0.0184
Number of glomeruli with Linear regression 0.014 0.41
lesions of FSGS/total number Spearman nonparametnc correlation
of glomeruli on RB 1
idiopathic nephrotic syndrome emerging from this analysis
were: (i) the percentage of pretreatment glomeruli with lesions
of FSGS, (ii) abnormal renal function before CsA treatment,
and (iii) a dosage greater than 5.5 mg/kg/day. Therefore, it is not
surprising to find that the most severe lesions were observed in
the 6 of 14 patients with FSGS whose serum creatinine was 132
44.5 mol/liter before starting CsA and who had been treated
with an average dosage of 6.26 1.05 mg/kg/day of the drug.
Long-term surveillance
Information on post-study evolution was obtained in all
patients.
Two patients, both aged 61 years, died of cancer, respec-
tively of the cervix and of the lung, after 20 and 14 months of
treatment. Details on these two cases have been provided
elsewhere [11].
Three patients were failures of CsA treatment and were
returned to conventional corticosteroid treatment.
Eight patients have been treated continuously for three to
seven years. As of June 1993 they were all continuing treat-
ment, and in all serum creatinine levels showed remarkable
stability. One of these patients became pregnant after five years
of treatment. CsA treatment was continued unchanged through-
out the pregnancy, at a dosage of 5 mg/kg/day, and she gave
birth by vaginal delivery to a normal child. During pregnancy,
serum creatinine decreased from 95 tmol per liter to 45 mol
per liter, indicating that CsA had not impeded the physiological
rise of GFR in pregnancy.
One of these patients deserves special mention. This 27-year-
old male with steroid-resistant nephrotic syndrome had a minor
form of FSGS (1 of 13 glomeruli with FSGS on initial renal
biopsy and 0 lesions concerning tubules and interstitium on
RB!). He was treated for 6.5 years with the relatively high
dosage of 6.9 mg/kg/day. At the time of RB2, complete remis-
sion was stable, serum creatinine was 93 tmol/liter, glomerular
lesions were unchanged and tubulointerstitial lesions were rated
only 1+.
In one patient the evolution was peculiar. This 22-year-old
male with steroid-dependent MCD went into remission with
CsA, and repeat biopsy after 12 months of treatment still
showed normal glomeruli. Treatment was tapered to a stop and
the nephrotic syndrome reappeared, with albuminuria, no mi-
crohematuria and normal renal function. A new attempt of CsA
treatment was unsuccessful and the patient was kept on low-
dose steroids. Seven months later, without any prior infectious
or other clinical manifestations, serum creatinine started to rise
rapidly while proteinuria increased and hematuria appeared.
Repeat biopsy, carried out at a time when serum creatinine was
424 j.z.mollliter, disclosed severe crescentic glomerulonephritis
with major tubulointerstitial lesions. Immunofluorescence
showed small, insignificant IgG and 1gM deposits and fibrin on
the crescents. Search for antineutrophil cytoplasmic antibodies
(ANCA) was negative. The patient was treated with methyl-
prednisolone pulses and cyclophosphamide. Renal function
improved but serum creatinine never decreased below 170
molIliter. Subsequently, renal function rapidly deteriorated,
and the patient began chronic hemodialysis two years after the
end of CsA treatment. No clinical manifestations have appeared
since starting dialysis, and an explanation for acute crescentic
pauci-immune, ANCA negative glomerulonephritis has not
been found.
In eight patients, all of whom had FSGS, CsA treatment was
stopped due to rapidly declining renal function which eventu-
ally led to chronic renal failure. The subsequent course was to
chronic hemodialysis. Two of these were transplanted. In one,
transplantation was successful. In the other, transplantation
was carried out two years after the end of unsuccessful CsA
treatment. The nephrotic syndrome relapsed immediately on
the allograft with recurrence of FSGS.
Fourteen patients were treated with CsA for 26 14.5
months (12 to 60). CsA was tapered to a stop and the patients
remained in remission, 11 without steroids and 3 with low-dose
steroid treatment. The follow-up of these 14 patients who
escaped CsA dependency ranges from eight months to six
years. The initial diagnosis was MCD in 10 and FSGS in 4.
However, of these four FSGS patients, the number of glomeruli
with focal and segmental lesions was only I of 35, 1 of 12 and 2
of 20 in three, reflecting a minor form of the disease. Only the
last one exhibited 8 of 25 glomeruli with lesions of FSGS on
RB!. On RB2 the severity of FSGS was confirmed by the
presence of five glomeruli with focal and segmental lesions plus
five obsolescent gloineruli out of a total of 18. In all these
patients, irrespective of histological lesions, last serum creati-
nine was 77 19 jmol per liter (50 to 115). A patient with
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severe lesions of FSGS on RB2 still has a serum creatinine of 91
tmol per liter despite the presence of 2+ tubular atrophy and
3+ interstitial fibrosis on RB2.
Discussion
CsA-induced remission depends on glomerular histology and
previous response to corticosteroids. Complete or partial re-
mission is obtained in about 70% of steroid-dependent and 30%
of steroid-resistant cases. A higher success rate in steroid-
resistant adults has been reported [18], but the definition of
steroid resistance was based on a course of glucocorticoid
treatment not exceeding six weeks; with a longer course of
treatment, some of these patients might have proven to be
steroid-sensitive [24]. Considering glomerular histology, the
rate of complete plus partial remission is in the order of 70% in
MCD, contrasting with only 40% in FSGS [12]. In the majority
of cases, during the first year of treatment CsA exerts a
suspensive, not a curative effect on nephrotic proteinuria.
Thus, maintaining remission usually requires treatment for
longer than one year and hence entails a risk of interstitial!
vascular lesions, striped fibrosis and deterioration of renal
function [14—17]. In 1989 Wingen et al [261 reported a precipi-
tous fall in GFR in five children with steroid resistant nephrotic
syndrome treated with CsA. Niaudet et al studied 43 children
with nephrosis in whom remission was obtained with CsA [19,
20]. Follow-up included monitoring of serum creatinine and one
to three repeat biopsies. Features of CsA toxicity appeared in
16 on the first repeat biopsy. On 13 further repeat biopsies the
rating of fibrosis increased in seven. In most cases, serum
creatinine did not significantly change despite aggravation of
fibrosis, indicating that the safety of continuing treatment
cannot entirely rely upon measurements of renal function, but
requires confirmation by renal histology, a conclusion fully
confirmed by our study in adults. Dermatologists made similar
observations in patients with psoriasis, who had no known prior
renal disease [27]. The report by the International Kidney
Biopsy Registry of Cyclosporine in Autoimmune Diseases [17]
analyzed the incidence of CsA nephropathy in 192 patients who
had been treated with the drug for insulin-dependent diabetes
mellitus, uveitis, psoriasis, Sjogren's syndrome or polychondri-
tis. The mean initial dosage of CsA was as high as 8.2 2.8 mg
per kg body weight per day and the duration of treatment was 4
to 39 months. Forty-one patients had biopsy-proven CsA-
induced nephropathy. Nephrotoxicity was correlated with
higher dosages of CsA, a higher maximal increase in serum
creatinine level above baseline, and age. The authors concluded
that, in these non-nephrological indications, the likelihood of
development of CsA-induced nephropathy could be minimized
by using doses no higher than 5 mg/kg/day and carefully
monitoring serum creatinine concentrations in order to reduce
dosage whenever these concentrations rise by more than 30%
above baseline.
Since no similar large-scale analysis had been published in
adult patients with idiopathic nephrotic syndrome, we under-
took this study to clarify the issue of functional and histological
tolerance of CsA treatment in patients with an underlying renal
disease, and to try to differentiate the consequences of pro-
tracted CsA treatment from the natural development of the
primary renal disease, especially FSGS. Several points in our
results call for discussion.
Reliability of renal biopsy rating
The drawbacks of studying renal pathology material semi-
quantitatively include the multiple pitfalls inherent in the renal
biopsy technique as well as the focal nature of renal lesions.
Interpretation of a renal biopsy depends on the number of
glomeruli present in the biopsy sample, the quality of biopsy
processing, including fixation, thickness of microtome slices,
quality and type of staining, and other technical procedures
which differ among pathology units. Also, the same biopsy can
be evaluated with wide variations by different pathologists, and
not all pathologists are familiar with the renal lesions of CsA
toxicity. To limit the above uncertainties, we tried to harmonize
biopsy processing and interpretation. The biopsies were inter-
preted by a single pathologist (L.H.N.), member of a Consen-
sus Panel of experts in the lesions of cyclosporin A nephrotox-
icity. To avoid technical faults, each paraflin-embedded biopsy
was referred by the various renal units to the reference labora-
tory for local cutting and staining. Each biopsy had previously
been given a code number and the expert pathologist was
unaware of any clinical and therapeutical details.
However, whatever precautions are taken to minimize tech-
nical drawbacks and subjective interpretation, there remain
further difficulties in interpreting the glomerular lesions and
interstitial damage in a renal biopsy. With regard to glomeruli,
it is known that FSGS begins and predominates in the jux-
tamedullary glomeruli and can be overlooked on the limited
sample of needle renal biopsy [28, 29]. This remains a possibil-
ity in this study, especially in cases where the initial diagnosis
was MCD and the second biopsy disclosed FSGS. However,
there was an average of 19.72 glomeruli per biopsy and samples
comprising less than 8 glomeruli represented only 12 of the total
72 biopsies (16.6%), which precludes major uncertainty due to
the vagaries of sampling. Also, in no instance was a diagnosis of
FSGS on the first biopsy followed by a diagnosis of MCD on the
second, meaning that the repeat biopsy sample was not misin-
terpreted.
Tubulointerstitial lesions
There was a meaningful difference in tubulointerstitial lesions
between patients with MCD and those with FSGS. These
differences were unrelated to duration of nephrotic syndrome or
to age. However, interpretation of post-CsA tubulointerstitial
lesions might also have been biased by differing CsA dosages
and/or lengths of treatment. Case by case screening found
seven patients in the FSGS and two in the MCD subgroups (on
RB2) whose CsA dosage was 6 or more mg/kg/day. Of those
with FSGS, two had been treated with more than 7.2 mg/kg/day
and had the most severe lesions in the series, typical of CsA
toxicity, with arteriolopathy and severe striped fibrosis. Two
patients in the MCD subgroup were treated respectively with 6
and 6.7 mg/kg/day. Repeat biopsy showed no vascular and only
trivial tubulointerstitial fibrosis. Thus, the consequences of CsA
overdosage seemed potentialized by the nature of the primary
renal disease, namely FSGS.
The average time elapsed between RB! and beginning of
treatment was 11.6 months. It was similar in MCD and FSGS.
Therefore, one cannot consider that tubulointerstitial lesions
were due to a longer period of development of FSGS, which had
falsely added to the lesions observed on RB2. These findings
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confirm that the primary renal disease played the major role in
the development of interstitial fibrosis and substantiate our
previous statement that steroid-resistant FSGS is a debatable
indication of CsA treatment [30].
In patients treated with CsA, interstitial lesions are inter-
preted as the consequence of drug toxicity. This was established in
uveitis and in heart transplant patients treated with high dose CsA
[14, 15] and confirmed in nonrenal autoimmune diseases [17, 27].
In all these indications, the kidney was presumably normal
before CsA. In our patients, who were treated with a lower dose
of CsA, interstitial fibrosis was more correlated with the type of
primary renal disease than with CsA treatment. This was
apparent both before treatment and after exposure to the drug.
On the pretreatment biopsy, we frequently found interstitial
lesions in patients with FSGS. Similar observations in adults
[31] and in children [8] have stressed the frequency of tubulo-
interstitial lesions in FSGS. More generally, several authors
have noted a poor prognostic significance of interstitial lesions
in glomerular diseases [32]. The same difference in the degree of
interstitial lesions between MCD and FSGS was found on
post-treatment biopsy. In this respect, it is striking to note the
rare observation of the so-called "typical" lesions of CsA
nephrotoxicity. These lesions have been extensively studied by
Mihatsch, Thiel, Ryffel [25]. They consist of a particular
artenolopathy on the one hand, and distinctive tubular cell
insult on the other. Both are associated with stripes of fibrosis
containing clusters of atrophic glomeruli. In our series CsA
arteriolopathy was found in five cases, including four with
initial lesions of FSGS and one who evolved from MCD to
FSGS. They all had been treated with dosages ranging from 6.6
to 7.8 mg/kg/day. As specified above, tubulointerstitial lesions
and fibrosis increased from RB I to RB2 but were clearly more
pronounced in patients with FSGS than in those with MCD,
indicating that exposure to CsA is not the only process leading
to the renal lesions in a patient treated with this drug. This
indicates that interpretation of CsA toxicity should be cautious.
Interstitial lesions should probably be attributed to the drug
only when they exhibit a typical striped or focal distribution, as
opposed to the diffuse fibrosis which may complicate FSGS. In
fact, the goal of repeat renal biopsy in a patient treated with
CsA is essentially to determine whether CsA can be safely
continued or should be stopped. From this viewpoint, accurate
distinction between CsA toxicity and primary renal disease is
secondary: whether typical of CsA toxicity or not, tubulointer-
stitial damage rated more than 2+ should lead to dosage
reduction or to withdrawal of CsA.
Aggravation of FSGS despite remission of proteinuria
An intriguing finding in this study was the aggravation of
glomerular lesions in patients with FSGS, despite remission of
proteinuria. Due to the small number of patients, this must be
cautiously interpreted, but we have given our reasons to believe
that it was not due to a sampling error. This is substantiated by
the findings of others. Ittel et al [33 and personal communica-
tion] treated 14 patients with CsA with idiopathic nephrotic
syndrome in whom the surveillance protocol was comparable to
that of our study. In two patients the initial diagnosis was
FSGS. CsA treatment induced drastic reduction of proteinuna.
Nevertheless, repeat biopsies disclosed worsening of focal
segmental sclerosis. In patients with MCD proteinuria de-
creased from 11.3 2.3 to 0.2 0.1 g/day. After a median of 52
months, repeat renal biopsies demonstrated that FSGS had
developed in three cases and subsequently CsA had to be
discontinued because of progression to renal failure. Taken
together, our observations and those of Ittel et al show that
lesions of FSGS may continue to develop despite reduction or
disappearance of proteinuria.
These findings cannot be commented on in the light of the
literature, because when remission of nephrotic syndrome is
obtained with corticosteroids or alkylating agents, repeat renal
biopsy is very rarely, if ever, carried out to verify the appear-
ance of the glomeruli. Interpretation is obviously hampered by
our limited number of cases. However, their theoretical interest
is substantial as they might suggest that the unidentified hu-
moral factor which induces the lesion of focal sclerosis contin-
ues to injure the glomerular podocyte/GBM complex despite
recovery of GBM permselectivity to albumin. We feel that such
functionallmorphologic dissociation should justify further re-
search which might shed some light on the obscure pathophys-
iology of FSGS.
Conclusion
This study indicates that tolerance of up to 5.5 mg/kg/day of
CsA is good in MCD patients with normal renal function and no
significant interstitial lesions on pre-C5A renal biopsy. In this
subset, and especially in patients with steroid toxicity, CsA
represents a new and promising treatment. Conversely, inter-
stitial lesions are frequent and developing in patients with
FSGS. Such lesions in patients with FSGS seem as relevant to
the natural history of the glomerular disease as to CsA. We
strongly advocate renal biopsy just before deciding to treat a
nephrotic patient with CsA. The finding, in steroid resistant
FSGS, of interstitial lesions rated 3+ should discourage pre-
scription of CsA, as such lesions are developing, and the parts
played by the natural history of the disease and by drug toxicity
are undetermined. Moreover, in FSGS, remission of nephrotic
syndrome with CsA should not necessarily be interpreted as
unequivocally favorable, as the renal lesions, including glomer-
ular sclerosis, may continue to develop silently. However, of 14
patients with FSGS and nephrotic syndrome stubbornly resis-
tant to previous, more conventional forms of therapy, CsA
obtained complete remission in five and partial remission in
five, with a definite improvement in their clinical condition. In
such cases, and even at the expense of increasing interstitial
fibrosis, the improvement of nephrotic syndrome might out-
weigh the long-term hazards of CsA toxicity.
Contrary to the relatively negative impression drawn from
treatment of FSGS, long-term CsA treatment of MCD appears
safe. In our cases safety has been assessed up to 78 months and
this length of follow-up seems sufficient to consider that several
years of treatment do not lead to chronic renal failure. How-
ever, even when remission has been obtained, irrespective of
the stability of renal function, repeat renal biopsy seems advis-
able at 12 months of treatment, considering that stabililty of
serum creatinine levels is not sufficient to exclude smoldering
interstitial fibrosis.
The most encouraging finding of this study was the unex-
pected number of fourteen patients in whom stable remission
was achieved and persisted after very progressively tapering
CsA to a stop following a treatment of one to five years. Six of
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these had lesions of FSGS either initially or on repeat renal
biopsy. This indicates that patients whose nephrotic syndrome
responds to cyclosporine are not invariably fated to indefinite
exposure to the drug in order to maintain remission. In other
terms, cyclosporine dependency is apparently the case for the first
year of treatment but is not obligatory after longer periods of time.
Before the advent of corticosteroid treatment of nephrosis, it
had been established that 30 to 40% of patients who had not
succumbed to the infectious and thrombotic complications of
the disease might enter spontaneous remission within five years
[3, 34—36]. It might be hypothesized that in some instances the
suspensive effect of cyclosporin A on the ill-identified immuno-
logic process which induces massive proteinuria provides the
time to reach this phase of extinction of the disease.
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